An Experimental Approach to Increase Selective Tumour Toxicity of Methotrexate
Thymidine protects mice bearing leukaemia L1210 and P388 from methotrexate toxicity without impairing antitumour activity. When thymidine containing pellets were implanted subcutaneously in L1210 leukaemia hearing mice, the therapeutic dose range of methotrexate was increased three-fold. The toxic effects of methotrexate in mice may be ascribed to a disturbance of de novo thymidylate synthesis but the antitumour activity must be due to a disturbance of some other folate dependent pathway.
KeywordsAnti Tumour Activity Folinic Acid Antitumour Activity Purine Biosynthesis L1210 Leukaemia
Unable to display preview. Download preview PDF.
- 2.Lefkowitz E., Papac R. C., Bertino J. R., “Head and Neck Cancer III Toxicity of 24 hr Infusions of Methotrexate and Protection by Leucovorin in Patients with Epidermoid Concinoma, Cancer,” Chem. Rep., 51, 305–311 (1967).Google Scholar
- 6.Tattersall M. H. N., Jaffe N., Frei Emil III, “The Pharmacology of Methotrexate Rescue Studies”. The University of Texas, M.D. Anderson Hospital and Tumor Clinic Synposium. The Pharmacologic Basis of Cancer Chemotherapy, Monograph (in press), 1974.Google Scholar
- 8.Capizzi R. L., Castro O., Aspnes G., “Treatment of Acute Lymphocytic Leukaemia with Intermittent High Dose Methotrexate and Asparaginase”, Proc. Amer. Asso. Cancer Res, 15, 182 (1974).Google Scholar
- 16.Lee D. J., Prensky W., “Measurements of DNA Turnover: Suppression of IUdR Reutilization in vivo by Long-acting Thymidine Pellets”, Fed. Proc., 31, 6737, (1972).Google Scholar
- 17.Lazarus H., Oppenheim S. O., Barett E. F., submitted for publication.Google Scholar